CW June 2005
Volume 14Issue Number 6 June 2005 ISSN 10593802 Bicalutamide Does Not Induce Osteoporosis in Men with Prostate CancerUnlike other commonly prescribed anti-androgen therapies for prostate cancer, bicalutamide (Casodex, AstraZeneca) does not cause bone mineral density (BMD) loss, according to a study of men with prostate cancer treated with the agent. Bicalutamide is a non-steroidal anti-androgen that blocks the action of testosterone without reducing testosterone levels, stated Vivek Wadhwa, Arrowe Park Hospital, Wirral, UK, at the American Urological Association 2005 Annual Meeting.
Go to Previous Page Go to Next Page Source & Additional Reading Vivek Wadhwa, Arrowe Park Hospital, Wirral, UK, at the American Urological Association 2005 Annual Meeting. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW June 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
